Ardent Health Grows Adjusted EBITDA by 46% in Q3, But Guidance Reflects Rising Industry Pressures
Operational Strength Drives Top-Line and Cash Flow Growth
Ardent Health, Inc. (NYSE: ARDT) delivered strong third-quarter 2025 results, with adjusted EBITDA jumping 46% year-over-year to $143 million and total revenue climbing 8.8% to $1.58 billion. Inpatient admissions surged by 5.8%, and inpatient surgeries advanced 9.7%, marking a continued rebound in core hospital activity. Operating cash flow also accelerated, reaching $154 million, a significant increase from $90 million a year earlier.
| Q3 2025 | Q3 2024 | Change (%) | |
|---|---|---|---|
| Total Revenue ($M) | 1,577 | 1,450 | +8.8 |
| Adjusted EBITDA ($M) | 143 | 98 | +46.3 |
| Admissions | 41,862 | 39,568 | +5.8 |
| Adjusted Admissions | 89,328 | 86,833 | +2.9 |
| Inpatient Surgeries | 9,732 | 8,871 | +9.7 |
| Total Surgeries | 32,545 | 32,091 | +1.4 |
| Net Patient Revenue per Adjusted Admission | 17,252 | 16,312 | +5.8 |
Guidance Revised Lower as Industry Headwinds Accelerate
Despite these positive trends, Ardent Health lowered its 2025 adjusted EBITDA guidance to a range of $530 million to $555 million (down from $575–$615 million previously). This move primarily reflects higher-than-expected professional fee expenses, which accelerated to 11% growth in the quarter, and more pronounced payor denials impacting revenue. While revenue guidance is reaffirmed at $6.2 to $6.45 billion, the outlook acknowledges that Q4 earnings will likely fall short of earlier targets.
| Metric | Previous 2025 Guidance | Updated 2025 Guidance |
|---|---|---|
| Total Revenue ($M) | 6,200–6,450 | 6,200–6,450 |
| Adjusted EBITDA ($M) | 575–615 | 530–555 |
| Diluted EPS | 1.73–2.01 | 0.85–1.03 |
Profitability Hit by One-Off Adjustments and Ongoing Costs
Ardent’s third quarter results also included notable non-recurring adjustments. A $43 million downward revenue revision stemmed from a change in the method of estimating accounts receivable collectability—reflecting new payor denial trends. In addition, professional liability reserves rose by $54 million due to litigation developments from a single former provider and broader social inflationary trends, although these impacts were excluded from adjusted EBITDA calculations.
Cost Management and Efficiency Efforts Underway
Facing persistent expense growth, Ardent has rolled out targeted measures such as workforce optimization and renegotiation of key payor and agency contracts. Management highlighted precision staffing, supply chain discipline, and operating room (OR) excellence as areas for near-term cost control. The company’s “IMPACT” program, focused on driving efficiencies, is already generating benefits, with some cost initiatives set to positively affect fourth quarter results.
Balance Sheet Remains Solid Amid Strategic Challenges
At the end of the quarter, Ardent maintained a robust liquidity position, with $609 million in cash and a net leverage ratio of just 1.0x (2.5x lease-adjusted), down from 2.7x in the prior quarter. Operating cash flow is notably strong, giving management flexibility to support operational investments and manage through a period of margin pressure.
Key Performance and Financial Indicators
| Metric | Q3 2025 | Q3 2024 | Y/Y % Change |
|---|---|---|---|
| Net (Loss) Income ($M) | -23.5 | 26.3 | - |
| Operating Cash Flow ($M) | 154 | 90 | +71 |
| Available Liquidity ($M) | 904 | - | - |
| Lease-Adjusted Net Leverage | 2.5x | 2.7x (Q2) | Improved |
Takeaway: Navigating Margin Pressure with Structural Growth Drivers
While Ardent Health’s operational strength stands out—highlighted by growing admissions, inpatient surgeries, and healthy cash flow—the revised guidance underscores industry-wide cost challenges and a more uncertain reimbursement environment. Management remains focused on cost controls and strategic initiatives, supported by strong liquidity and a balanced approach to growth. As efficiency efforts take effect and non-recurring expenses fade, Ardent’s fundamental demand and disciplined management may help sustain long-term margin improvement.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI